Transcept Pharmaceuticals to Present at the BIO Investor Forum on October 26, 2011
POINT RICHMOND, Calif., Oct. 24, 2011 /PRNewswire/ — Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present at the BIO Investor Forum in San Francisco on October 26, 2011 at 9:30 a.m. PT.
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Transcept is developing IntermezzoÃ‚® (zolpidem tartrate sublingual tablet) as a prescription sleep aid for use as needed when a middle of the night awakening is followed by difficulty returning to sleep. Transcept and Purdue Pharmaceutical Products L.P. are parties to a collaboration agreement for the development and commercialization of IntermezzoÃ‚® in the United States. Transcept is also developing TO-2061, a low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with approved first-line pharmacotherapy. For further information, please visit the Transcept website at: www.transcept.com.
Transcept Pharmaceuticals, Inc.
Director, Corporate Communications
SOURCE Transcept Pharmaceuticals, Inc.